NASDAQ$TWST
Twist Bioscience Corporation · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported record revenue and announced decisive actions to accelerate path to profitability.
Twist Bioscience reported a strong quarter, exceeding revenue guidance and breaking the $60 million revenue threshold for the first time. The company also announced decisive and proactive actions aimed at accelerating its path to profitability.
- Total revenues for the second quarter of fiscal 2023 were $60.2 million, up 25% compared to $48.1 million for the same period of fiscal 2022.
- Total orders received for the second quarter of fiscal 2023 were $64.2 million compared to $55 million for the same period of fiscal 2022.
- Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share.
- As of March 31, 2023, the company had $387.7 million in cash, cash equivalents and investments.
Headline financials
Revenue & EPS history
Twist Bioscience · Revenue · Quarterly
$60.2M
Revenue by segment
Twist Bioscience · $218M total across 2 segments · Q3 2023
- NGS Applications$120M+23.7%55.0%
- DNA Synthesis & Protein$98M+22.5%45.0%
Forward guidance
Twist Bioscience provided updated financial guidance for fiscal year 2023 and 2024, including revenue, gross margin, and operating expenses.
Tailwinds
- Revenue for Q3 2023 is expected to be approximately $60 million to $61 million.
- Revenue for Q4 2023 is expected to be approximately $62 million to $63 million.
- Gross margin for Q4 2023 is expected to be approximately 36%.
- Operating expenses for DNA data storage are expected to be $40 million for fiscal year 2024.
- Fiscal year end cash is projected to be $220 million for fiscal year 2024.
Headwinds
- Revenue guidance for fiscal year 2023 is expected to be approximately $235 million to $238 million, compared to previous guidance of $261 million to $269 million.
- SynBio revenue is expected to be $96 million to $98 million, compared to previous guidance of $104 million to $106 million.
- NGS revenue is expected to be $113 million to $114 million, compared to previous guidance of $120 million to $123 million.
- Biopharma revenue is expected to be $26 million, compared to previous guidance of $37 million to $40 million.
- Gross margin for fiscal 2023 is expected to be 35-36%, compared to previous guidance of approximately 39-40%.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.1%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+0.8%
Avg return
30 days after
47%
14 / 30 earnings
Positive
+29.7%
Q4 2023
Best reaction
-23.2%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -7.3% | -5.9% | +19.6% | |
| Q1 2026 | +13.8% | -5.9% | -10.2% | |
| Q4 2025 | -10.0% | -14.9% | +3.4% | |
| Q2 2025 | -8.5% | -16.9% | -20.8% | |
| Q1 2025 | +0.7% | -0.1% | -19.7% | |
| Q4 2024 | +12.0% | +14.5% | +20.9% | |
| Q3 2024 | -14.6% | -16.0% | -18.5% | |
| Q2 2024 | +28.9% | +34.9% | +31.1% | |
| Q1 2024 | +9.5% | +5.1% | +16.9% | |
| Q4 2023 | +29.7% | +24.9% | +81.5% | |
| Q3 2023 | +14.9% | +9.3% | +14.0% | |
| Q2 2023 | +3.6% | +2.1% | +26.0% | |
| Q1 2023 | -23.2% | -15.2% | -37.1% | |
| Q4 2022 | +0.8% | +0.5% | -0.6% | |
| Q3 2022 | +20.8% | +12.4% | -17.2% | |
| Q2 2022 | -9.9% | -16.3% | -12.6% | |
| Q1 2022 | -1.0% | +6.0% | -21.0% | |
| Q4 2021 | -12.6% | -14.1% | -22.4% | |
| Q3 2021 | -9.1% | -15.8% | -7.6% | |
| Q2 2021 | +6.2% | -9.4% | -12.4% | |
| Q1 2021 | -16.8% | -5.5% | -38.1% | |
| Q4 2020 | -9.9% | -0.8% | +44.3% | |
| Q3 2020 | -7.2% | -16.3% | -4.8% | |
| Q2 2020 | +5.1% | +4.6% | +0.7% | |
| Q1 2020 | +21.3% | +14.0% | +31.4% | |
| Q4 2019 | +4.6% | +5.8% | -15.5% | |
| Q3 2019 | -11.2% | -11.8% | -13.9% | |
| Q2 2019 | -9.9% | -9.7% | -3.9% | |
| Q1 2019 | -9.2% | -11.8% | -6.9% | |
| Q4 2018 | -9.2% | -9.4% | +18.6% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro